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AbstrAct
Objective To compare the efficacy of embedded nurse-led 
versus conventional physician-led follow-up on disease 
activity in patients with rheumatoid arthritis (RA).
Methods In a systematic literature search, we identified 
randomised controlled trials (RCTs) reporting on the 
efficacy of nurse-led follow-up on disease control in 
patients with RA compared with physician-led follow-up. 
Primary outcome was disease activity indicated by Disease 
Activity Score (DAS)-28. Secondary outcomes were: patient 
satisfaction, physical disability, fatigue, self-efficacy and 
quality of life. Outcomes were assessed after 1-year and 
2 year follow-ups.
Results Seven studies representing five RCTs, including 
a total of 723 participants, were included. All but one 
study included stable patients in low disease activity or 
remission at baseline. No difference in DAS-28 was found 
after 1 year (mean difference (MD) −0.07 (95% CI −0.23 
to 0.09)). After 2 years, a statistically significant difference 
was seen in favour of nurse-led follow-up (MD −0.28 (95% 
CI −0.53 to −0.04)). However, the difference did not reach 
a clinically relevant level. No difference was found in 
patient satisfaction after 1 year (standard mean difference 
(SMD) −0.17 (95 % CI −1.0 to 0.67), whereas a statistical 
significant difference in favour of nurse-led follow-up was 
seen after 2 years (SMD: 0.6 (95% CI –0.00 to 1.20)).
Conclusion After 1 year no difference in disease activity, 
indicated by DAS-28, were found between embedded 
nurse-led follow-up compared with conventional 
physician-led follow-up, in RA patients with low disease 
activity or remission.
IntroductIon
Treatment of rheumatoid arthritis (RA) aims 
to achieve remission or low disease activity 
(treat-to-target) in order to stop or minimise 
joint erosion, normalise functioning and 
improve the patients’ quality of life.1 Hence, 
important elements in the RA treatment 
strategy such as early diagnosis and initiation 
of pharmacological treatment, quick escala-
tion of drugs to a clinically effective level and 
adjustment of the dose when there are signs 
of disease activity are considered important.1 
This requires close monitoring of disease 
activity and adjustments of the pharmacolog-
ical therapy in patients with RA throughout 
the course of their disease. In patients with 
moderate or high disease activity, it is recom-
mended that measurements of disease activity 
are obtained monthly and in patients with 
sustained low disease activity or remission 
every 6 months.1
Increased life expectancy means that more 
people will develop RA in the future and 
thus need treatment and follow-up. Even as 
treatment is generally becoming more effec-
tive and better tolerated, many countries 
experience an unmet demand for rheumatol-
ogists coinciding with a demand for greater 
cost-effectiveness. Thus, different alterna-
tives to conventional outpatient physician-led 
follow-up have been investigated, for example, 
to allow nurse-led consultations to become 
embedded in the follow-up of RA in daily 
clinical practice.2–5 Furthermore, it has been 
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Key messages
What is already known about this subject?
 ► In the recent years, evidence of the involvement 
of nurses in care and control of disease activity in 
patients with rheumatoid arthritis (RA) has increased.
What does this study add?
 ► By conducting a meta-analysis, we have created 
an overview that can ease intrepretation of the 
evidence.  After 1 year, there were no differences in 
disease activity between nurse-led and phycisian-
led follow-up.
How might this impact on clinical practice?
 ► Our findings may promote the implementation of 
nurse-led follow-up supervised by physicians in the 
future.
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recommended that nurses should participate in disease 
management to improve patient-preferred outcomes, 
such as fatigue, throughout the disease course.6 It has also 
been recommended that patients with RA should have 
access to a nurse throughout the course of their disease 
to improve their understanding and disease manage-
ment and for enhanced satisfaction.6 Studies have shown 
that nurse-led care may contribute to promote patients’ 
self-management skills and thus their level of self-efficacy.7 
The increasing involvement of nurses in the follow-up 
of patients with RA has been recognised and described 
in recent European treatment recommendations.1 The 
essential question remains, however, whether the involve-
ment of nurses in the follow-up care can achieve the 
same degree of disease control, indicated by DAS-28, as 
when the follow-up is performed by physicians alone. In 
addition, it is interesting whether nurses can contribute 
to enhanced patient satisfaction and self-efficacy. These 
questions need a systematic evaluation of the evidence. 
Hence, our objective was to conduct a systematic review 
and meta-analysis to investigate the efficacy of embedded 
nurse-led versus conventional physician-led follow-up in 
the treat to target strategy in RA.
Methods
Search strategy
A systematic literature search was performed in the 
following electronic databases: MEDLINE (Ovid), 
Embase (Ovid), the Cochrane Central Register of 
Controlled Trials (CENTRAL), PsycINFO (ProQUEST), 
CINAHL (EBSCO), Web of Science (Thomson Reuters) 
and Scopus (Elsevier). There was no time limit back in 
time. The search ended in December 2016. We searched 
for all randomised controlled trials (RCTs) using the 
methodological filter for RCTs outlined in the Cochrane 
Handbook8; variations of this filter, or other validated 
filters, were used for other databases.
A search for possible ongoing trials was performed 
through  ClinicalTrials. gov, ISRCTN registry, UK Clin-
ical, Research Network Study Portfolio and MRC Clinical 
Trials Unit. Dissertations and theses were located through 
ProQuest Dissertations & Theses Global. Reference lists 
of relevant articles and conference proceedings were 
searched manually, and the included studies were also 
made subject to citation analysis in Web of Science. No 
language restrictions were imposed, and databases were 
searched from inception date and forward. Protocol of 
the searches in the different databases can be found as 
online supplementary file 1 .
Selection of studies
All the included studies were RCTs reporting on the effect 
of nurse-led follow-up in managing disease control in 
RA compared with physician-led follow-up. Patients with 
RA were diagnosed according to the American College 
of Rheumatology 1997/2010 criteria.9 10 This implied 
nurse-led follow-up of outpatients with RA in hospi-
tals where nurses performed assessment of tender and 
swollen joints, evaluated blood samples and monitored 
the medical treatment in order to assess the patients’ 
disease activity.
Outcome measures
The primary outcome was disease activity indicated by 
Disease Activity Score (DAS)-28 C reactive protein (CRP) 
or erythrocyte sedimentation rate (ESR) or DAS-44.11 12 
The DAS-28 CRP/ESR combines single measures into an 
overall continuous measure of disease activity in RA and 
includes a 28 tender and swollen joint count together 
with either CRP or ESR and a patient global assessment 
of disease activity.12 DAS-44 includes a 44-swollen joint 
count, CRP/ESR and a patient global assessment.12
Secondary outcomes were patient satisfaction, physical 
disability, quality of life, fatigue and self-efficacy.
Data extraction and management
Each potentially relevant study was independently 
reviewed by two reviewers (all studies were reviewed by 
ADT and by JP, BAE or IKR). Disagreement was resolved 
through discussion until consensus was obtained. From 
each selected trial, the following data were collected: 
general study information (author information, affil-
iation, country and funding) number of randomised 
individuals for each treatment group, characteristics of 
the participants in the intervention and control groups, 
type of intervention, type of comparator, follow-up times 
(ie, longest follow-up period), disease activity, level of 
physical disability, level of fatigue, self-efficacy and patient 
satisfaction. We also extracted the number of subjects 
who withdrew from the study (dropouts) for each treat-
ment group. Data were extracted using the web-based 
software platform Covidence (www. covidence. org).
Assessment of risk of bias and overall quality
We used the Cochrane 'Risk of Bias' tool13 to assess bias 
in six domains: random sequence generation, allocation 
concealment, blinding to participants, blinding to assess-
ment, withdrawals (attrition bias) and selective outcome 
reporting.14 Risk of bias was assessed at the level of each 
outcome, independently by two reviewers (ADT and by 
JP, BAE or IKR). In addition to risk of bias, the ‘Grading 
of Recommendations Assessment, Development and 
Evaluation’ (GRADE) was used to evaluate the total body 
of evidence by further assessment of three domains: 
inconsistency (the variation across studies), indirectness 
(ie, differences in patient population) and imprecision 
(95% confidence interval (CI)).15
Statistical methods
Heterogeneity was tested using the χ2 test, and inconsis-
tency was evaluated via the I2 index, which expresses the 
percentage of total variation across studies.16 Data were 
entered into Review Manager 5.3 (http:// tech. cochrane. 
org), and a meta-analysis was performed as a random 
effect model by default, because we expected the study 
populations to vary regarding factors that might influ-
ence our primary outcome, DAS-28, that is, regarding 
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underlying treatment.17 All outcomes were continuous. 
Disease activity was measured by DAS-28 in all studies 
allowing change from baseline until end of follow-up to 
be estimated by calculating mean difference (MD) with 
95% CI. All secondary outcomes (patient satisfaction, 
self-efficacy, physical activity and fatigue) were measured 
on different scales across the studies (table 1) and were 
thus estimated by standard mean difference (SMD) with 
95% CI. When outcomes within the same concept are 
measured on different scales, SMD treats effect as a unit 
less measure by dividing the difference in mean changes 
from baseline until the end of follow-up by the pooled 
SD.18
Stratified analyses were performed according to the 
duration of the observation period (12 months vs >12 
months). Forest plots were used to assess the results. A 
two-sided p value<0.05 was considered to be statistically 
significant.
reSultS
Description of studies
A total of 1052 studies were identified, and seven RCTs 
representing five studies were finally included in the 
meta-analysis (figure 1).2 3 19–23 Three of the included 
studies comprised data from the same study cohort, the 
AMBRA (AMBulant behandling af Reumatoid Artrit – 
Outpatient care of established RA) study.2 19 20 Nurses in 
the included studies were described as: nurses, rheuma-
tology nurses, clinical nurse specialists or experienced 
rheumatology nurses trained in joint assessment (table 1). 
Most studies included patients with RA; however, one 
study included patients with RA, ankylosing spondylitis 
(AS), psoriatic arthritis (PsA) and juvenile idiopathic 
arthritis or undifferentiated polyarthritis,21 and one study 
included patients with RA and PsA.22 The percentages 
of patients with RA in these two studies were 53% and 
62%, respectively. Due to the relatively low number of 
studies included in the meta-analysis, we chose to depart 
from our protocol and included these studies in the 
primary analysis in order to provide sufficient power to 
the meta-analysis; instead we downgraded the quality of 
evidence for indirectness according to the GRADE meth-
odology24 and performed a sensitivity analysis without 
these two studies.21 22 Only one study included patients 
with a DAS-28 ESR >3.2.23 In all studies, the nurse-led 
follow-up was supervised by physicians.
One study described the mean change in DAS-28 
graphically3 but did not provide data for the meta-anal-
ysis. We contacted the authors, but unfortunately, data 
were no longer available.
Patient satisfaction was measured on both the Leeds 
Satisfaction Scale25 and a visual analog scale (VAS) confi-
dence and satisfaction scale.26
One study assessed physical disability by the Arthritis 
Impact Measurement Scale.27 The remaining studies 
used the Health Assessment Questionnaire for assess-
ment of physical disability.28
Quality of life was assessed by the SF-36 (mental 
part),29 the RA quality of life scale30 and the European 
Quality of Life-5 Dimensions.31 Fatigue was measured by 
a VAS fatigue scale,32 except in one study,3 where it was 
measured in minutes, and these data were not included 
in the analysis. Self-efficacy was measured by the Arthritis 
Self-Efficacy Scale33 and two studies also reported data 
from the Rheumatoid Arthritis Self-Efficacy Question-
naire (RASE).2 34 Results from the RASE were, however, 
not used in the meta-analyses. A description of the 
included studies is shown in table 1, and a list of excluded 
studies can be found in online supplementary file 2 .
critical appraisal
All included studies were RCTs and. in general, the 
quality was moderate to low. An evidence table showing 
the grading of the evidence for each outcome is shown 
in online supplementary file 3 . None of the studies were 
double blinded due to the type of intervention. Two of 
the included studies had ensured assessor blinding of 
the assessment of disease activity,2 23 and all but one22 
performed intention-to-treat analyses. Risk of bias assess-
ments across all outcomes are summarised in figure 2.
effect of nurse-led versus physician-led follow-up
Disease activity
Data concerning disease activity were based on 534 
patients in four studies that all reported a DAS-28 CRP/
ESR.2 21–23 There was no statistically or clinically significant 
difference in disease activity between nurse-led versus 
physician-led follow-up after 1 year (MD −0.07 (95% CI 
−0.23 to 0.09)) (figure 3.1). The quality of the evidence 
was moderate (online supplementary file 3). Leaving out 
the two studies that included patients with other types of 
inflammatory arthritis (IA) than RA21 22 did not alter the 
estimates (−0.15 (95% CI −0.40 to 0.10); however. it did, 
as expected, increase imprecision.35
Two of the studies addressed the effect after 2 years.2 21 
These studies included a total of 249 patients, and both 
included patients with low disease activity or in remission. 
A statistically but not clinically relevant difference was 
found in favour of nurse-led follow-up (MD −0.28 (95% CI 
−0.53 to 0.04)). Furthermore, the CIs were wide including 
both no difference (0.04) and nurse-led follow-up being 
more effective than physician-led follow-up (−0.53) and 
thus, the quality of the evidence was downgraded due to 
imprecision35 (figure 3.2) (online supplementary file 3). 
The between variance was low with I2 values of 0% at both 
1-year and 2-year follow-ups.
In the study that could not be included in the meta-anal-
ysis due to missing data,3 no statistically significant 
difference was found between the two groupssupporting 
the overall estimate of the meta-analysis.
Patient satisfaction
Data concerning patient satisfaction after 1 year was based 
on 537 patients from four different studies.2 3 22 23 No 
statistically significant difference was found in patients’ 
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Figure 1 Flow diagram showing the selection of studies.
satisfaction between nurse-led versus physician-led 
follow-up (SMD −0.17 (95% CI −1.0 to 0.67)) (figure 3.3). 
Heterogeneity was high for this outcome (I2=95%). 
When leaving out the one study that included patients 
with a baseline DAS-28 >3.2,23 no heterogeneity was 
found (I2=0%), and a small statistically significant differ-
ence in favour of nurse-led follow-up was seen (SMD 0.24 
(95% CI 0.03 to 0.45)). We performed the analyses again 
without the studies that included patients with other 
types of IA.22 This did not alter the overall estimates 
(−0.27 95% CI −1.38 to 0.83).
At 2-year follow-up, a statistically significant difference 
in patient satisfaction was seen in favour of nurse-led 
follow-up (SMD: 0.60 (95% CI 0.00 to 1.20)). However, 
only two studies reported data from 2-year follow-up,2 21 
and heterogeneity was high (I2=76%) (figure 3.4). When 
omitting the study with other types of patients with IA,21 
the effect size decreased from strong to moderate (0.33 
(95% CI 0.03 to 0.62)). The quality of evidence was low 
due to heterogeneity and imprecision (online supple-
mentary file 3).
Self-efficacy
Data on self-efficacy after 1 year were based on a total of 
367 patients from two studies.2 23 After 1 year, a small but 
statistically significant difference was seen in favour of 
nurse-led follow-up (SMD: 0.30 (95% CI 0.07 to 0.53)) 
(figure 3.5). Heterogeneity was low (I222%), and the 
quality of evidence was moderate (online supplementary 
file 3). Only one study assessed self-efficacy after 2 years.2 
However, the results stayed more or less the same but 
became more imprecise (SMD: 0.46 (95% CI 0.16 to 
0.76)) (figure 3.6).
Other secondary outcomes
Common for the remaining three secondary outcomes 
(physical disability, fatigue and quality of life) was that 
very small non-statistically significant differences were 
seen between the two groups. Forest plots for these 
outcomes can be found in online supplementary file 4 .
discussion
In this meta-analysis, we found no differences in the effi-
cacy to achieve or sustain disease control by embedded 
nurse-led follow-up compared with conventional physi-
cian-led follow-up in patients with RA with low disease 
activity or in remission.
To the best of our knowledge, this is the first meta-anal-
ysis evaluating the effect of nurse-led care in RA. A recent 
systematic review found nurse-led care to be effective 
and safe. However, the authors decided not to carry out 
a meta-analysis with heterogenerity as their argument.36 
A previous systematic review from 2011 was inconclusive 
due to lack of power (only few studies could provide data 
for the primary outcome).37
We have shown that for most outcomes heterogene-
rity was generally low and further, the body of evidence 
has markedly improved since 2011. This has enabled 
us to include more relevant studies and allowed us to 
perform a useful meta-analysis. By calculating SMDs 
when outcomes within the same concept were measured 
on different scales18 and by using random effect model 
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Figure 2 Risk of bias for each reported outcome across the included studies.
by default, we have taken into account the possible varia-
tions among studies.17
Unlike the previous studies, we excluded the multi-
centre study by Tijhuis et al38 as it compared inpatient 
care with nurse-led follow-up, while our study compared 
nurse-led with physician-led follow-up for outpatients. We 
also excluded the study of Ryan et al39 as it dealt with drug 
monitoring rather than monitoring of disease activity.
Our findings is consistent with findings within other 
chronic diseases, that is, a Cochrane review regarding the 
benefits from adding a nurse specialist to routine care in 
the management of type 1 or type 2 diabetes,40 an RCT 
regarding the management of childhood asthma by a 
paediatrician or asthma nurse41 and a Cochrane review 
regarding nurse-led versus physician-led in adult asthma 
care.42
Apart from disease control, nurse-led follow-up may 
contribute with additional value in the overall treat-
ment and care in RA. Nurse-led follow-up provides the 
opportunity to use the scarce rheumatology resources 
in a more efficient way by offering patients different 
types of follow-up throughout their disease course. 
Rheumatologists will therefore be able to focus on diag-
nostics, medical prescription and treatment of patients 
with continuing high disease activity or comorbidities.
In the past years, we have seen an increasing tendency 
to involve nurses in the care and control of disease 
activity in patients with RA.6 43 44 Based on the additional 
professional perspectives nurses add to RA treatment and 
care, consideration should be given to involve them in 
routine follow-up, independently of whether rheumatol-
ogist resources are scarce or not. Studies have shown that 
patients value nurse-led follow-up, because it provides 
continuity of the healthcare provider, makes patients feel 
secure and makes them feel that they have easy access to 
help.19 45–48 Furthermore, a mixed-method study found 
that nurses focus more on socioemotional issues, whereas 
physicians tend to be more task focused.49 Nurses also 
focus on supporting the patients to manage life with 
their disease, which may explain why nurses’ support may 
increase the patients’ self-efficacy.6
Still, it is important to point out that, in most of the 
included studies, nurses had many years of experience 
with rheumatology (10+ years). This indicates that 
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Figure 3 Forest plots showing pooled mean and standard mean differences (SMDs) for disease activity, patient satisfaction 
and self-efficacy in trials comparing nurse-led with physician-led follow-up among patients with rheumatoid arthritis (RA) 
after 1 and 2 years. Disease activity measured by DAS-28 CRP/ESR, patient satisfaction measured by Leeds Satisfaction 
Questionnaire or NRS Satisfaction Scale and self-efficacy measured by Arthritis Self-Efficacy Scale (ASES) and RASE. DAS-
28, Disease Activity Score; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; RASE, Rheumatoid Arthritis Self-
Efficacy Questionnaire.
less-experienced nurses will need proper training and 
supervision by both rheumatologists and senior nurses 
before they can take over some of the follow-up consul-
tations in RA and undertake extended roles such as 
examinations of the joints and identification of signs of 
flare-ups and insufficient pharmacological treatment.
Strengths and limitations
The internal validity of our meta-analysis was ensured by 
the application of a systematic and strict methodology 
throughout the whole review process. An experienced 
research librarian (TF) undertook a systematic, thorough 
search of the literature to identify all studies meeting 
the inclusion criteria for this review. A priori, our review 
protocol was made permanently available online (http://
www. crd. york. ac. uk/ PROSPERO/, PROSPERO id no. 
42015026151), allowing other researchers to check that 
the review has been performed according to the protocol. 
The general quality of the evidence of the included studies 
was moderate. By using the well-recommended GRADE 
methodology to assess the overall quality of the studies, 
we ensured a systematic and transparent process of the 
review.35 In this connection, it is important to underline 
that in general the included studies were well conducted 
and of high quality. However, the nature of the intervention 
renders blinding, which was not possible in the included 
studies. Thus, the quality of the evidence will a priori be 
downgraded due to the possibility of information bias.35 
Despite this, we have high confidence that the true effect 
was likely to be close to the estimated effect.35 However, 
our study has some limitations that merit further discus-
sion. The meta-analytic approach creates an overview that 
can ease interpretation. However, although our selection 
criteria were strict, the interventions in the included studies 
were not exactly the same with respect to the frequency of 
follow-up and supervision provided by rheumatologists to 
the nurses. In addition, the content in the nurse-led and 
physician-led follow-ups is not described in detail in the 
included studies and may vary based on local culture and 
legislation.
Furthermore, it can be regarded as a limitation that we 
did not predefine factors of importance regarding safety, 
that is, with respect to reported drug adverse events and 
that we did not include the frequency of follow-up as an 
outcome in order to be able to control for these variables.
Variability in study populations with respect to disease 
activity is likely to be the main cause for the high inter-
study heterogeneity discovered in the outcome for 
patient satisfaction.
All the included studies had dropouts <10%. Different 
reasons for dropouts were given (including comorbidity, 
death and non-compliance). All but one of the included 
studies22 did, however, use intention-to-treat analysis, by 
which they took a possible selection bias into account. 
Only one study included patients with RA and with high 
disease activity.23 Thus, it remains unresolved whether 
nurse-led follow-up is applicable in patients with high or 
uncontrolled disease activity. In recent years, the prev-
alence of patients with low disease activity or remission 
has, however, increased markedly due to the improved 
pharmacological treatment and the implementation of 
the treat to target strategy. Hence, overall, approximately 
two-thirds of the patients with RA in daily clinical prac-
tice will fall into this category, and thus support this type 
of intervention.1 Finally, it must be regarded a limitation 
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that some of the included studies included patients with 
other diagnoses than RA.21 22 In order to take this into 
account, we have downgraded the evidence quality due 
to indirectness in line with the GRADE methodology24 
and have provided sensitivity analysis excluding these 
studies. In conclusion, after 1 year, no clinical or signifi-
cant differences were found in the efficacy of embedded 
nurse-led follow-up compared with physician-led 
follow-up on disease activity, indicated by DAS-28 in RA 
patients with low disease activity or remission.
Given that the quality of the evidence was low for disease 
activity measured after 2 years, we recommended that 
nurse-led follow-up is always implemented in tandem with 
physicians. However, based on our study, we conclude that 
it is feasible to involve nurses in disease management in 
patients with RA with low disease activity or in remission.
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